US 7,399,747 B1
	Peptides carrying substances across the blood brain barrier
Philippe Clair, Nimes (France); Michel Kaczorek, Montferrier-sur-Lez (France); and Jamal Temsamani, Nimes (France)
Assigned to SYNT:EM, Nimes (France)
Appl. No. 9/857,000 PCT Filed Nov. 26, 1999, PCT No. PCT/FR99/02938 § 371(c)(1), (2), (4) Date Sep. 07, 2001, PCT Pub. No. WO00/32236, PCT Pub. Date Jun. 08, 2000.
Claims priority of application No. 98 15074 (FR), filed on Nov. 30, 1998.
Int. Cl. A61K 38/00 (2006.01); C07K 5/00 (2006.01)

U.S. Cl. 514—15  [514/13; 424/9.1; 530/326; 530/328; 435/325]

4 Claims

1. A method for treatment of a Central Nervous System (CNS) disease, comprising administering, to a subject suffering from a disease of the CNS, a conjugate comprising an active substance in an amount sufficient to treat said disease of the CNS, wherein the active substance is coupled directly or indirectly by a covalent bond to one of the following peptides: SynB1 (SEQ ID NO: 11) or SynB3 (SEQ ID NO: 12), and wherein said active substance is an active chemical molecule in the treatment of the CNS disease, and said disease of the CNS is selected from the group consisting of brain cancer, pain and meningitis.